Chinese biopharma firm Everest Medicines raises $451m in HK IPO

Chinese biopharma firm Everest Medicines raises $451m in HK IPO

Fu Wei (right), CEO of CBC Group and Chairman of Everest Medicines and Kerry Blanchard (left), CEO of Everest Medicines celebrate the listing of Everest Medicines on the HKEX on October 9, 2020. Source: CBC Group

Everest Medicines, a Chinese clinical-stage biopharmaceutical firm created by CBC Group, has raised almost HK$3.50 billion ($451 million) in an initial public offering (IPO) in Hong Kong on Friday.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter